Nanoscope’s MOGENRY BLA Accepted by FDA for Retinitis Pigmentosa

Dallas, Texas, USA, September 9, 2026

FDA Accepts BLA for Gene-Agnostic Retinitis Pigmentosa Therapy

The MOGENRY BLA seeks approval for treatment of adults with retinitis pigmentosa and severe vision loss. The FDA’s acceptance initiates the formal regulatory review process and represents a transition for MOGENRY from clinical development toward potential commercialization. Nanoscope said the application is supported by clinical data demonstrating improvements in visual function among patients with advanced RP. The company is pursuing MOGENRY as a gene-agnostic therapy, meaning its mechanism is intended to address retinal dysfunction without requiring identification of a patient’s specific disease-causing mutation. This approach could have important implications for RP, which encompasses a large and genetically diverse group of inherited retinal disorders. More than 100 genes have been associated with inherited retinal degeneration, making mutation-specific therapeutic development challenging and leaving many patients without an applicable targeted treatment. The BLA acceptance therefore represents a significant milestone for a therapy designed to potentially address a broader RP population rather than a single genetic subtype.

MOGENRY Uses Optogenetic Technology to Restore Visual Signaling

MOGENRY is based on Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) technology, an optogenetic approach designed to restore light sensitivity in retinal cells that have lost normal photoreceptor function. Retinitis pigmentosa progressively damages rod and cone photoreceptors, the specialized retinal cells responsible for detecting light. As these cells degenerate, patients can experience night blindness, narrowing of the visual field and ultimately severe vision loss. Because photoreceptor degeneration can continue despite the absence of a functional genetic pathway, researchers have been exploring approaches that can bypass damaged photoreceptors. MOGENRY is designed to introduce an MCO protein into retinal cells through a single intravitreal administration. The engineered protein is intended to make retinal cells responsive to light, potentially allowing remaining retinal circuitry to transmit visual signals even after substantial photoreceptor loss. This mechanism distinguishes MOGENRY from traditional gene replacement approaches that attempt to correct a specific genetic mutation. The therapy instead seeks to restore light sensitivity downstream of the genetic defect, potentially allowing treatment across multiple RP genotypes.

Clinical Data Support Regulatory Review

The BLA submission is supported by data from clinical development programs evaluating MOGENRY in patients with severe vision loss caused by RP. Nanoscope has reported improvements in visual function and functional vision measures following treatment, providing the clinical foundation for the regulatory submission. The company has previously conducted a randomized, controlled Phase 2b study evaluating MCO-010, the active component of MOGENRY, in patients with advanced RP. The program was designed to evaluate whether optogenetic therapy could improve visual function in individuals who have limited treatment options because of advanced retinal degeneration. Nanoscope has also reported long-term follow-up data intended to characterize the durability and safety of the treatment. These findings are important because any therapy intended for severe inherited retinal disease must demonstrate not only an appropriate benefit-risk profile but also evidence that functional improvements can persist over time. Importantly, FDA acceptance of the BLA is not an approval decision. The agency will conduct a full review of the application before determining whether MOGENRY’s benefits outweigh its potential risks for the proposed indication. The therapy remains investigational until regulatory approval is granted. If approved, MOGENRY could represent a significant development in the treatment of advanced inherited retinal disease, particularly for patients whose specific RP mutations lack an approved targeted therapy. For cGxP.wire readers, the announcement highlights the progress of optogenetic therapeutics, gene-agnostic drug development and advanced retinal medicine from clinical research toward regulatory review. The FDA’s acceptance of the MOGENRY BLA places Nanoscope’s program at a critical stage where regulatory assessment will determine whether the investigational therapy can move into clinical practice.

Source: Nanoscope Therapeutics press release